Armis Biopharma

Executive Summary

Armis Biopharma is a private San Diego-based biotechnology company developing novel antimicrobial therapies based on its patented Veriox® Technology platform. The platform is designed as a single-stop antimicrobial and antitoxin solution, targeting a broad range of infectious diseases. Founded in 2018, the company aims to reduce the severity and frequency of infections that cause human suffering and death. While specific financial details and development stage remain undisclosed, the Veriox platform represents a differentiated approach in the infectious disease space, potentially offering advantages over conventional antibiotics by combining antimicrobial and antitoxin activities. With the rise of antimicrobial resistance, Armis's technology could address critical unmet needs in hospital-acquired infections and biodefense. However, the company is early-stage and privately held, limiting visibility into its financial health, clinical pipeline, and regulatory progress. The success of Armis will depend on its ability to advance Veriox through preclinical and clinical development, secure funding, and establish strategic partnerships. The infectious disease market remains competitive, but Armis's novel platform could carve a niche if safety and efficacy data are positive.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement60% success
• Q4 2026Preclinical Proof-of-Concept Data Release70% success
• Q1 2027Orphan Drug Designation for Lead Candidate40% success